2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical (ISRG) based on the provided data:

**1) Return Rate Analysis**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **Relative Performance:** ISRG outperformed the S&P 500 (VOO) over the period examined. The cumulative return for ISRG was 111.62%, compared to 102.21% for VOO.
*   **Divergence:** The current divergence is 10.3. With a fluctuation range between -37.8 to 98.9, its relative divergence is 35.2, suggesting ISRG is performing relatively moderately compared to its past performance.
*   **Alpha, Beta Analysis:**

    | Year       | CAGR    | MDD   | Alpha  | Beta  | Cap(B) |
    |------------|---------|-------|--------|-------|--------|
    | 2015-2017  | 68.0%   | 77.6% | 40.0%  | -0.1  | 43.6   |
    | 2016-2018  | 64.0%   | 72.2% | 49.0%  | -0.0  | 57.2   |
    | 2017-2019  | 54.0%   | 72.2% | 31.0%  | 0.2   | 70.6   |
    | 2018-2020  | -6.0%   | 80.4% | -29.0% | 0.3   | 97.8   |
    | 2019-2021  | 29.0%   | 80.4% | -18.0% | 0.6   | 128.8  |
    | 2020-2022  | -23.0%  | 80.4% | -22.0% | 1.2   | 95.1   |
    | 2021-2023  | -17.0%  | 77.5% | -18.0% | 1.7   | 120.9  |
    | 2022-2024  | 36.0%   | 77.5% | 15.0%  | 1.7   | 187.1  |
    | 2023-2025  | 74.0%   | 72.7% | 7.0%   | 0.8   | 205.3  |

    *   **CAGR:** The Compound Annual Growth Rate shows significant variability across different periods, with strong growth in some years and declines in others.
    *   **MDD:** Maximum Drawdown indicates substantial risk, with MDDs consistently high.
    *   **Alpha:** Alpha has fluctuated widely, indicating periods of outperformance and underperformance relative to the benchmark.  The negative Alphas in recent periods suggest underperformance.
    *   **Beta:**  Beta has generally increased over time, suggesting ISRG has become more sensitive to market movements.  The beta values are low (close to zero).
    *   **Cap(B):**  Market capitalization has generally increased, indicating overall growth in the company's value, although there have been periods of contraction.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** \$572.63
*   **Last Market Data:** Price decrease of -0.48 from previous close of \$575.4.
*   **Moving Averages:**
    *   5-day SMA: \$576.066
    *   20-day SMA: \$565.8713
    *   60-day SMA: \$536.0183

    The current price is below the 5-day SMA but above the 20-day and 60-day SMAs. This suggests a possible short-term downtrend, but a longer-term uptrend.

**3) RSI, PPO, and Investment Signals**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended).
*   **RSI:** 60.11 (Approaching overbought territory, but not yet there).
*   **PPO:** 0.0062 (Slightly positive, indicating upward momentum, but weak).
*   **Hybrid Signal:** "cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80)" Suggests a strong buy signal.
*   **Recent Divergence Change:** 1.3 (+) Indicates short-term rise
*   **Expected Return:** 24.5% Long-term expected return exceeding S&P 500 if invested for 2+ years.
*   **Price Change:** The recent price change of -0.48 suggests a minor fluctuation issue (a slight pullback, but not a sharp decline).

**4) Recent News & Significant Events**

*   **Analyst Opinions:** Predominantly positive.
*   **Golden Crossover:** A golden crossover (50-day moving average crossing above the 200-day moving average) is generally considered a bullish signal.
*   **High Margins & Discount:** Articles highlight strong margins and potential undervaluation.
*   **AI Surgical Systems:** Mention of innovations in AI surgical systems is a forward-looking positive.
*   **Mirova US LLC Sold Shares:** This might be a cause for minor concern, depending on the size of the sale and the reason behind it.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-22 | 1.98 | 2.51 B$    |
| 2025-07-23 | 1.84 | 2.44 B$    |
| 2025-04-23 | 1.95 | 2.25 B$    |
| 2024-10-18 | 1.59 | 2.04 B$    |
| 2025-10-22 | 1.59 | 2.04 B$    |

*   **Trend:**  EPS and revenue have generally increased over the past few quarters, indicating positive growth. However, there appears to be a duplicated date `2025-10-22`.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | \$2.51B   | 66.36%        |
| 2025-06-30 | \$2.44B   | 66.31%        |
| 2025-03-31 | \$2.25B   | 64.69%        |
| 2024-12-31 | \$2.41B   | 68.04%        |
| 2024-09-30 | \$2.04B   | 67.41%        |

*   **Revenue:** Revenue is generally increasing quarter-over-quarter.
*   **Profit Margin:** Profit margins are consistently high, demonstrating strong profitability.

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-09-30 | \$16.93B   | 4.16%  |
| 2025-06-30 | \$17.85B   | 3.69%  |
| 2025-03-31 | \$17.11B   | 4.08%  |
| 2024-12-31 | \$16.43B   | 4.17%  |
| 2024-09-30 | \$15.58B   | 3.63%  |

*   **Equity:** Equity has generally increased.
*   **ROE:** Return on Equity is relatively stable, indicating consistent profitability relative to shareholder equity.

**7) Comprehensive Analysis (Summary)**

Intuitive Surgical (ISRG) appears to be a fundamentally strong company with a positive outlook. Here's a summary:

*   **Performance:** ISRG has outperformed the S&P 500, although its recent Alpha is negative, suggesting underperformance relative to its benchmark in the short term.
*   **Technical Indicators:**  The moving averages suggest a possible short-term downtrend, but an overall upward trend. The RSI is approaching overbought levels, but the PPO indicates weak upward momentum.
*   **Market Sentiment:** Analyst opinions are overwhelmingly positive. Recent news highlights strong margins and potential undervaluation. The golden crossover is a bullish signal.
*   **Financials:** ISRG has strong and growing revenues, very healthy profit margins, increasing equity, and consistent ROE.
*   **Risks:** High maximum drawdowns and recent share sales by Mirova US LLC need to be taken into account.
*   **Investment Recommendation:** The MRI suggests high investment recommendation. The Hybrid Signal advocates a 90% buy. The expected return of 24.5% seems promising.

**Overall Conclusion:** While there are some minor risks and short-term concerns, ISRG appears to be a good investment opportunity based on its strong fundamentals, positive market sentiment, and promising growth prospects. However, investors should carefully consider their own risk tolerance and conduct further due diligence before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.